China's National Healthcare Security Administration said it established a
drug-pricing and procurement credit-evaluation system in Aug 2020 and, in a
three-year review, found some medical institutions had weak internal controls
leading staff to take repeated, large commercial bribes from discredited
suppliers. After a prior Shanghai stent-balloon bribery exposure and reports of
a 5,000 yuan-per-stent kickback at Hebei Medical University Second Hospital, the
NHSA said that hospital was involved in nine criminal judgments in H2 2025.
Hospital staff accepted bribes 46 times; the largest single amount was 16.58 mln
yuan, the longest-running scheme lasted 11 years, and the cumulative implicated
amount reached 184 mln yuan.
